Ali Raza
Plus aucun poste en cours
Historique de carrière de Ali Raza
Anciens postes connus de Ali Raza
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Sosei Co. Ltd.
 Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Directeur/Membre du Conseil | 18/01/2011 | - |
| President | - | - | |
| ASTRAZENECA PLC | Directeur Technique/Scientifique/R&D | - | - |
| Corporate Officer/Principal | - | 16/02/2011 | |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01/06/2008 | - |
Formation de Ali Raza
| The University of Manchester | Undergraduate Degree |
| University of London | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 5 |
| Japon | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| President | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sosei Co. Ltd.
Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
